Vonesh Edward F, Snyder Jon J, Foley Robert N, Collins Allan J
Baxter Healthcare Corporation, Applied Statistics Center, Round Lake, Illinois 60073, USA.
Kidney Int. 2004 Dec;66(6):2389-401. doi: 10.1111/j.1523-1755.2004.66028.x.
While the survival ramifications of dialysis modality selection are still debated, it seems reasonable to postulate that outcome comparisons are not the same for all patients at all times. Trends in available data indicate the relative risk of death with hemodialysis (HD) compared to peritoneal dialysis (PD) varies by time on dialysis and the presence of various risk factors. This study was undertaken to identify key patient characteristics for which the risk of death differs by dialysis modality.
Analyses utilized incidence data from 398,940 United States Medicare patients initiating dialysis between 1995 and 2000. Proportional hazards regression identified the presence of diabetes, age, and the presence of comorbidity as factors that significantly interact with treatment modality. Stratifying by these factors, proportional and nonproportional hazards models were used to estimate relative risks of death [RR (HD:PD)].
Of the 398,940 patients studied, 11.6% used PD as initial therapy, 45% had diabetes mellitus (DM), 51% were 65 years or older, and 55% had at least one comorbidity. Among the 178,693 (45%) patients with no baseline comorbidity, adjusted mortality rates in nondiabetic (non-DM) patients were significantly higher on HD than on PD [age 18-44: RR (95% CI) = 1.24 (1.07, 1.44); age 45-64: RR = 1.13 (1.02, 1.25); age 65+: RR = 1.13 (1.05, 1.21)]. Among diabetic (DM) patients with no comorbidity, HD was associated with a higher risk of death among younger patients [age 18-44: RR = 1.22(1.05, 1.42)] and a lower risk of death among older patients [age 45-64: RR = 0.92 (0.85, 1.00); age 65+: RR = 0.86 (0.79, 0.93)]. Within the group of 220,247 (55%) patients with baseline comorbidity, adjusted mortality rates were not different between HD and PD among non-DM patients [age 18-44: RR = 1.19 (0.94, 1.50); age 45-64: RR = 1.01 (0.92, 1.11); age 65+: RR = 0.96 (0.91, 1.01)] and younger DM patients [age 18-44: RR = 1.10 (0.92, 1.32)], but were lower with HD among older DM patients with baseline comorbidity [age 45-64: RR = 0.82 (0.77, 0.87); age 65+: RR = 0.80 (0.76, 0.85)].
Valid mortality comparisons between HD and PD require patient stratification according to major risk factors known to interact with treatment modality. Survival differences between HD and PD are not constant, but vary substantially according to the underlying cause of ESRD, age, and level of baseline comorbidity. These results may help identify technical advances that will improve outcomes of patients on dialysis.
尽管透析方式选择对生存率的影响仍存在争议,但可以合理推测,并非所有患者在任何时候的结局比较都是相同的。现有数据趋势表明,与腹膜透析(PD)相比,血液透析(HD)的相对死亡风险会因透析时间和各种风险因素的存在而有所不同。本研究旨在确定透析方式导致死亡风险存在差异的关键患者特征。
分析利用了1995年至2000年间开始透析的398,940名美国医疗保险患者的发病数据。比例风险回归确定糖尿病的存在、年龄和合并症的存在是与治疗方式有显著相互作用的因素。按这些因素进行分层,使用比例和非比例风险模型来估计死亡的相对风险[RR(HD:PD)]。
在研究的398,940名患者中,11.6%使用PD作为初始治疗,45%患有糖尿病(DM),51%年龄在65岁及以上,55%至少有一种合并症。在178,693名(45%)无基线合并症的患者中,非糖尿病(非DM)患者中HD的调整死亡率显著高于PD[18 - 44岁:RR(95%CI)= 1.24(1.07,1.44);45 - 64岁:RR = 1.13(1.02,1.25);65岁及以上:RR = 1.13(1.05,1.21)]。在无合并症的糖尿病(DM)患者中,HD在年轻患者中与较高的死亡风险相关[18 - 44岁:RR = 1.22(1.05,1.42)],而在老年患者中与较低的死亡风险相关[45 - 64岁:RR = 0.92(0.85,1.00);65岁及以上:RR = 0.86(0.79,0.93)]。在220,247名(55%)有基线合并症的患者中,非DM患者中HD和PD的调整死亡率没有差异[18 - 44岁:RR = 1.19(0.94,1.50);45 - 64岁:RR = 1.01(0.92,1.11);65岁及以上:RR = 0.96(0.91,1.01)],年轻DM患者中也是如此[18 - 44岁:RR = 1.10(0.92,1.32)],但在有基线合并症的老年DM患者中HD的死亡率较低[45 - 64岁:RR = 0.82(0.77,0.87);65岁及以上:RR = 0.80(0.76,0.85)]。
HD和PD之间有效的死亡率比较需要根据已知与治疗方式相互作用的主要风险因素对患者进行分层。HD和PD之间的生存差异并非恒定不变,而是根据终末期肾病的潜在病因、年龄和基线合并症水平有很大差异。这些结果可能有助于确定能改善透析患者结局的技术进步。